Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

被引:49
作者
Kim, Hyo Song [2 ,6 ]
Kim, Eun Kyoung [1 ]
Jun, Hyun Jung [2 ]
Oh, Sung Yong [3 ]
Park, Keon Woo [4 ]
Lim, Do Hyoung [4 ]
Lee, Soon Il [4 ]
Kim, Jung Han [5 ]
Kim, Kyoung Mee [7 ]
Lee, Dae Ho [1 ]
Lee, Jeeyun [2 ]
机构
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematooncol,Dept Med, Seoul, South Korea
[3] Dong A Univ, Coll Med, Dong Canc Ctr A, Dept Internal Med, Pusan, South Korea
[4] Dankook Univ, Sch Med, Dept Hematol Oncol, Cheonan, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea
[6] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea
关键词
COOPERATIVE-ONCOLOGY-GROUP; POPULATION-BASED INCIDENCE; MUCOSAL MELANOMA; ORAL-CAVITY; CUTANEOUS MELANOMA; MUCOUS-MEMBRANES; KIT; NECK; HEAD; EXPRESSION;
D O I
10.1186/1471-2407-10-167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We performed multicenter study to define clinical characteristics of noncutaneous melanomas and to establish prognostic factors patients who received curative resection. Methods: Of the 141 patients who were diagnosed of non-cutaneous melanoma at 4 institutions in Korea between June 1992 and May 2005, 129 (91.5%) satisfied the selection criteria. Results: Of the 129 noncutaneous melanoma patients, 14 patients had ocular melanoma and 115 patients had mucosal melanoma. For mucosal melanoma, anorectum was the most common anatomic site (n = 39, 30.2%) which was followed by nasal cavity (n = 30, 23.3%), genitourinary (n = 21, 16.3%), oral cavity (n = 14, 10.9%), upper gastrointestinal tract (n = 6, 4.7%) and maxillary sinus (n = 5, 3.9%) in the order of frequency. With the median 64.5 (range 4.3-213.0) months follow-up, the median overall survival were 24.4 months (95% CI 13.2-35.5) for all patients, and 34.6 (95% CI 24.5-44.7) months for curatively resected mucosal melanoma patients. Adverse prognostic factors of survival for 87 curatively resected mucosal melanoma patients were complete resection (R1 resection margin), and age > 50 years. For 14 ocular melanoma, Survival outcome was much better than mucosal melanoma with 73.3% of 2 year OS and 51.2 months of median OS (P = .04). Conclusion: Prognosis differed according to primary sites of noncutaneous melanoma. Based on our study, noncutaneous melanoma patients should be treated differently to improve survival outcome.
引用
收藏
页数:8
相关论文
共 37 条
  • [21] Primary malignant melanoma of the stomach
    Jelincic, Z
    Jakic-Razumovic, J
    Petrovic, I
    Cavcic, AM
    Unusic, J
    Trotic, R
    [J]. TUMORI JOURNAL, 2005, 91 (02): : 201 - 203
  • [22] Cancer statistics, 2008
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Hao, Yongping
    Xu, Jiaquan
    Murray, Taylor
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) : 71 - 96
  • [23] MALIGNANT-MELANOMA OF MUCOUS-MEMBRANES - A CLINICOPATHOLOGICAL STUDY OF 13 CASES IN JAPANESE PATIENTS
    KATO, T
    TAKEMATSU, H
    TOMITA, Y
    TAKAHASHI, M
    ABE, R
    [J]. ARCHIVES OF DERMATOLOGY, 1987, 123 (02) : 216 - 220
  • [24] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, TJ
    Borden, EC
    Blum, RH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17
  • [25] A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
    Kirkwood, JM
    Manola, J
    Ibrahim, J
    Sondak, V
    Ernstoff, MS
    Rao, U
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1670 - 1677
  • [26] Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
    Lutzky, Jose
    Bauer, Juergen
    Bastian, Boris C.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (04) : 492 - 493
  • [27] Macak J., 1998, Pathologica (Genoa), V90, P388
  • [28] Manolidis S, 1997, CANCER, V80, P1373, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1373::AID-CNCR3>3.0.CO
  • [29] 2-G
  • [30] Head and neck mucosal melanoma
    Mendenhall, WM
    Amdur, RJ
    Hinerman, RW
    Werning, JW
    Villaret, DB
    Mendenhall, NP
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 626 - 630